In court documents, AstraZeneca claims that the Covid vaccination may have an uncommon adverse effect

London: According to the Daily Telegraph, AstraZeneca has stated in court filings that there may be an uncommon adverse effect from the COVID vaccination.

According to court records obtained by the Daily Telegraph, the pharmaceutical company is being sued for more than £100 million (about Rs 1,000 crore) in a class action over allegations that their vaccination caused death and severe damage in 51 instances. This is the context in which the comment was made.

While AstraZeneca disputes the allegations, it acknowledges in a court filing filed in February that the COVID vaccination “may, in extremely rare circumstances, cause thrombosis with thrombocytopenia syndrome,” a condition that results in blood clots and a low platelet count.
The vaccine, which was produced in Pune by the Serum Institute of India (SII), was marketed as Covishield in India. SII was reached, but he refused to comment.

Jamie Scott, a father of two, is one of the plaintiffs. Following his AstraZeneca vaccination in April 2021, he had a blood clot and a brain hemorrhage that stopped him from working, leaving him with lasting brain damage.
With the approval of the UK regulator, the MHRA, the product information for the AstraZeneca-Oxford vaccine was updated in April 2021 to include the possibility that, in extremely rare circumstances, the vaccine could act as a trigger for thrombosis with thrombocytopenia syndrome (TTS).According to the UK media, AstraZeneca notes that this update was thoroughly recorded and made accessible to the public.
The vaccination that Oxford University and the UK produced is no longer in use.
Attorneys for families suing the pharmaceutical corporation contend that the vaccination was not as safe as people had a right to believe. They claim the maximum £12,000 (more than Rs 12 lakh) payment they may get from the UK government-run vaccination compensation plan is insufficient, and they are suing the company under the Consumer Protection Act of 1987.
AstraZeneca vaccine recipients received at least 158 of the 163 reimbursements granted by the UK government program by February of this year, according to figures acquired by the Daily Telegraph via a Freedom of Information request.
“The AstraZeneca-Oxford vaccine has continuously been shown to have an acceptable safety profile and regulators around the world consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects,” an AstraZeneca spokesperson told TOI.